• Outlook Therapeutics resubmitted its BLA to the FDA for ONS-5010/LYTENAVA (bevacizumab-vikg) to treat wet age-related macular degeneration.
• The FDA upheld the company’s appeal of a Complete Response Letter, concluding effectiveness evidence is sufficient, eliminating the need for additional trials.
• The resubmission was designated Class 1, setting an FDA decision deadline within 60 days of receipt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010846PRIMZONEFULLFEED9729303) on June 01, 2026, and is solely responsible for the information contained therein.